Objective: This study aimed to assess the in vivo effects of estradiol treatment on arterial gene expression in atherosclerotic postmenopausal female monkeys.
T he concept that estradiol has atheroprotective effects is supported by observational studies demonstrating that premenopausal women are less susceptible to most cardiovascular diseases than men of similar age, but that the risk of cardiovascular disease increases after menopause. 1, 2 In a multitude of preclinical studies, estradiol has been shown to have protective effects against early atherogenesis, but the protective effects are diminished in arteries that have already developed plaques. 3<6 Moreover, clinical trials suggest that there may be an increased risk of cardiovascular disease events when treatment with estrogens and progestogens is initiated in women with preexisting coronary heart disease 7 (The Heart and Estrogen/ Progestin Replacement Study) and in older postmenopausal women. 8 Some evidence suggests that initiation of estrogen therapy at the time of the menopausal transition (when vasomotor symptoms and hot flushes are greatest) may produce greater beneficial effects on atherosclerosis than initiation of such treatment in late menopause. 3 Loss of estradiol protection has been the source of much controversy in the discussion of the safety and efficacy of postmenopausal estrogen replacement, and the mechanism of reversal remains obscure. Estrogen receptors > and A are expressed in arterial tissues; thus, direct effects of estrogen on arterial gene expression are probable. 9 Inverse relationships between estrogen receptor expression and atherosclerosis have been observed at the protein 10 and messenger RNA 11<13 levels in a variety of studies. It is possible that the loss of estrogen receptor expression in atherosclerotic arteries makes them refractive to direct estradiol effects. It is also probable that the complex cellular environment of atherosclerotic lesions responds differently to estrogens than normal arteries or early less complicated lesions.
Cynomolgus monkeys develop atherosclerotic lesions in peripheral (iliac) and coronary arteries after consuming a diet of saturated fats and cholesterol at amounts similar to those consumed by people in North America. The ovariectomized cynomolgus monkey has been used extensively to study the effects of estrogens on atherosclerosis in postmenopausal subjects. 14<16 The current study was undertaken to examine the in vivo effects of oral estradiol on global gene expression patterns in the iliac arteries of ovariectomized cynomolgus monkeys with established atherosclerosis.
METHODS

Animals and study design
This study used eight adult female surgically postmenopausal cynomolgus macaques (Macaca fascicularis) aged 11 to 27 years. The monkeys had been ovariectomized for 4 to 6 years before the initiation of the study. The animals were housed in stable social groups of three to four animals each and consumed various semipurified diets for 6.5 years. During the study, the monkeys continued to consume a typical North AmericanYtype diet, which contained 0.20 mg of cholesterol/Calorie, 29.6% fat, and 19.8% animal source protein (casein/lactalbumin). Monkeys were fed approximately 120 kcal/kg body weight once daily for 8 months of the study.
All monkeys underwent an iliac biopsy procedure similar to that previously described 11, 12 to obtain pretreatment tissue samples (left common iliac artery). The iliac artery was divided into three equal segments (segments a, b, and c; from proximal to distal). Segment a was frozen in liquid nitrogen and stored at j70-C for a separate study. Segment b (endothelial surface up) was placed flat on filter paper, fixed in 4% paraformaldehyde for 24 hours, transferred to 70% ethanol, and embedded in paraffin for sectioning and staining of atherosclerotic plaque. Measurement of plaque size was performed as previously described. 12, 17, 18 Segment c was cleaned of excess adventitia, placed in RNA later A (Sigma R-0901) for 24 hours, and stored at j70-C before RNA extraction.
Animals were randomized to the control group or the estradiol treatment group, taking social groupings into consideration. Estradiol (Estrace A ; 1-mg tablets) was administered in the diet (n = 4) at a human equivalent dose of 1 mg/day, the dose commonly taken by postmenopausal women. Control animals received the same diet without hormone (n = 4). After 8 months, all monkeys were euthanized, and the contralateral (right) common iliac artery was collected and processed as described above.
Plasma lipids and lipoproteins
Blood samples were obtained at baseline and at 3, 6, and 8 months for the measurement of lipid levels. 18, 19 Plasma lipids/ lipoproteins/total plasma cholesterol (TPC) concentrations, highdensity lipoprotein cholesterol (HDL-C) concentrations, and plasma triglycerides (TG) were determined in the Comparative Medicine Clinical Chemistry and Endocrinology Laboratory using reagents (ACE cholesterol, ACE HDL-C, and ACE TG) and instrumentation (ACE ALERA autoanalyzer) from Alfa Wasserman Diagnostic Technologies (West Caldwell, NJ). TPC and HDL-C were standardized to calibrated control values from the Centers for Disease Control and PreventionYNational Heart, Lung, and Blood Lipid Standardization Program. Intra-assay and interassay coefficients of variation were less than 5% for all analytes. NonYHDL-C, which approximates the sum of lowdensity lipoprotein cholesterol and very-low-density lipoprotein cholesterol, was calculated by subtracting HDL-C from TPC.
All animal procedures conformed to state and federal laws and were conducted in compliance with the standards of the US Department of Health and Human Services and with the guidelines established by the Wake Forest University Animal Care and Use Committee. The facilities and laboratory animal program of Wake Forest University are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.
RNA extraction and DNA microarrays
Total RNA was extracted from the iliac arteries and analyzed as described previously. 11, 20 Analysis of gene expression in the cynomolgus monkey iliac arteries used CodeLink Whole Human Genome Bioarrays (Applied Microarrays, Tempe, AZ), as described previously. 11 For gene expression analysis, data from pretreatment iliac arteries were compared with data from posttreatment iliac arteries for both estradiol-treated animals and vehicle control animals. Genes that differed in expression from baseline in both vehicle control and estradiol-treated lists were removed from further consideration.
Real-time polymerase chain reaction
Two-step real-time reverse transcription (RT)Ypolymerase chain reaction (PCR) was used to confirm the expression of selected genes that had been shown to be differentially expressed by DNA microarray, as described previously. 11 Complementary DNA (cDNA) was synthesized from 0.1 Kg of total RNA by RT using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). The real-time PCR used cDNA from the RT reaction and thermally stable AmpliTaq Gold DNA polymerase for DNA amplification. Predesigned primers and probes were obtained from TaqMan Gene Expression Assays ( 
Statistical analysis
Unless specified otherwise, all data are expressed as mean (SEM). The experimental number (n) was four per group, and P value was set to 0.05. 
DNA microarrays
GeneSpring GX 7.0 software (Agilent, Santa Clara, CA) was used for the statistical analysis of DNA microarray data. The P value was set to 0.05 for paired t test. The Benjamini-Hochberg false discovery rate of 0.05 was used for multiple testing correction.
PCR data
Real-time PCR data were analyzed by paired t test followed by Newman-Keuls post hoc test when a significant F was found.
Atherosclerotic lesion sizes
Atherosclerotic lesion sizes were analyzed by analysis of variance.
Plasma lipid variables
Plasma lipid variables averaged over the treatment period were analyzed by analysis of covariance using baseline values as covariate. All parameters were normally distributed, except for TG, which was log-transformed to improve normality.
RESULTS
Analysis of gene expression in the monkey iliac arteries in response to estradiol in posttreatment arteries compared with pretreatment arteries, corrected for control, yielded a list of genes for which expression differed significantly with a P value of 0.05 or less. The exclusion criteria were as follows: transcribed sequences with no name and no known function (because there is currently no means to identify the functions of those genes), genes for which expression values were too near the limits of detection of the assay (mean relative expression values G1.0), and genes for which fold expression values were less than twofold different from control values (values between 0.5-fold and 2.0-fold of control values). The expression values of down-regulated genes ranged from 0.26-fold to 0.5-fold of control values, whereas the expression values of up-regulated genes ranged from 2-fold to 6.9-fold of control values. Based on these criteria, estradiol treatment resulted in a differential expression of 132 genes (Table 1) . Of those genes, 106 were upregulated in response to estradiol, and 26 were down-regulated.
For a subset of genes with evidence of increased expression in response to estradiol, microarray findings were followed up with real-time RT-PCR analyses for verification purposes (Fig. 1) . IGF1 was up-regulated by estradiol in the monkey iliac arteries, as identified by DNA microarray analysis of gene expression ( Fig. 1A) and confirmed by RT-PCR ( Fig. 1B) . IGFBP4 (Fig. 1C , D) and IGFBP5 (Fig. 1E, F) were also up-regulated in the iliac arteries in response to estradiol. Several components of the Wnt signal transduction pathway were also upregulated in the monkey iliac arteries in response to estradiol, as initially shown by DNA microarray and confirmed by real-time RT-PCR. These included SFRP2 ( Fig. 2A, B) , SFRP4 (Fig. 2C, D) , LRP6 ( Fig. 2E, F) , and WISP2 (also called CCN5; Fig. 2G, H) . A large number of other genes involved in signal transduction were represented in the estrogenregulated gene list, including connective tissue growth factor (CTGF), endoglin (ENG), and endothelial cell growth factor 1 (ECGF1; Table 1) .
Several extracellular matrix genes were among those that were proportionally increased in estrogen-treated animals, including the >1 chain of type I collagen (COL1A1), the >2 chain of type VI collagen (COL6A2), fibulin 2 (FBLN2), and others. The transcript for heparan sulfate proteoglycan 2 (perlecan) was also among the genes with significantly increased expression in the estrogen-treated group (Table 1) . Plasma lipid levels were assessed at baseline and at 3, 6, and 8 months of the study. TG levels increased, but no other significant differences in plasma lipids in response to estradiol treatment were identified ( Table 2) .
The data set for these DNA microarrays has been deposited at the National Center for Biotechnology Information Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo), as recommended by Minimum Information About a Microarray Experiment standards, 22 and can be accessed through Gene Expression Omnibus Series accession numbers GSE37187 and GSE26326 (GSM646190, GSM646191, GSM646194, GSM646195, and GSM646186-9).
DISCUSSION
The treatment paradigm used in this study was designed to mimic the effects of estradiol treatmentVinitiated after a long period of estrogen deficiencyVon postmenopausal women. The power of this experimental design is that it provides Bbefore[ and Bafter[ snapshots of gene expression in atherosclerotic iliac arteries in response to estradiol. Moreover, each animal served as its own control in this experimental design, which provided an internal control for atherosclerosis that would not be practical or possible in a human population. (A, B) , insulin-like growth factor binding protein 4 (IGFBP4) (C, D), and insulinlike growth factor binding protein 5 (IGFBP5) (E, F) in the iliac arteries of cynomolgus monkeys fed a high-fat/high-cholesterol diet in response to treatment with estradiol. A, C, E: Differential gene expression data from DNA microarray analysis. B, D, F: Data from real-time reverse transcriptionYpolymerase chain reaction (RT-PCR) analysis. Data are expressed as mean (SEM); n = 4 per group. Bars with different letter superscripts denote that the data for those groups are significantly different from each other (P G 0.05).
As in women, there was considerable heterogeneity in the presence and size of atherosclerotic plaque at the time of initiation of estradiol treatment. The presence of atherosclerosis has been shown to dramatically alter gene expression in the arteries, 11, 23, 24 which may originate in part from the variety of cell types present in atherosclerotic lesions. 12, 13, 25 The variance in gene expression attributable to the influence of atherosclerosis and multiple cell types present may have masked subtle responses to estrogen or may have inflated other estrogen responses.
These data demonstrate a substantial effect of estrogen on gene expression in the iliac arteries despite the minimal effect of estrogen on plasma lipid levels and its lack of effect on atherosclerotic plaque size. The data are consistent with previous reports of a limited effect of estrogen on lipid levels 14, 18 and the inability of estrogen treatment to reduce atherosclerotic plaque size in well-established atherosclerosis 3,26<28 in cynomolgus monkeys. However, the presence of genomic estrogen receptors in the vasculature is well established. 29 Indeed, estrogen has been shown to affect a broad scope of receptor-mediated physiological functions in the vasculature, ranging from angiogenesis to reductions in vascular tone, modulation of inflammatory reactions, and other functions. 5, 6 Because genomic estrogen receptors act as ligand-activated transcription factors, 30 it is logical to examine the effects of estrogen on gene expression in the arteries despite the limited effects of estrogen on lipid levels or atherosclerotic plaque size.
The most important limitation of this study is the relatively small number of monkeys that were assessed for global gene expression analyses, as necessitated by the expense of the model. Because the presence of a complicated plaque with a variety of unique cell types (endothelial, smooth muscle, macrophage, fibroblast, T-cell, B-cell, etc) has such a profound effect on the expression profile of the whole tissue, 11 it is probable that the presence of the plaque at least partially masked the effects of estradiol on gene expression. Thus, genes that were observed to respond to estradiol in the presence of an environment compromised by the presence of atherosclerosis represent a combination of the effects of estrogen on individual phenotypes and an alteration in the populations of those cell types. Unfortunately, there was not enough statistical power in the group sizes to dissect out the effects of estradiol on gene expression in arteries with small/ absent plaque versus medium or large plaque. Some genes that have been previously shown to be regulated by estradiol in the vasculature 31<33 were not identified in this study; we hypothesize that the presence of atherosclerotic plaque in the arteries is responsible, at least in part, for this discrepancy. Other possible explanations for the discrepancy include the following: different sensitivities of the methods used in this experiment versus other experiments, different lengths of exposure to hormone, different statistics (eg, multiple testing correction may eliminate genes whose expression is actually different), or different responses to hormone in different vascular beds.
Several expression profile changes in response to estrogen suggest that there were profound effects on cell phenotypes and/or cell populations present in the artery. For example, twofold to fourfold increases in the expression of extracellular matrix genes, such as type I and type VI collagen, are more representative of a smooth muscle or a fibroblastic phenotype than a macrophage phenotype. Indeed, the ontology of the extracellular matrix was one of the few ontologies in which all of the differentially expressed genes were upregulated in response to estrogen. These data suggest that there may be some changes in arterial cell populations in response to estrogen. FBLN2, an extracellular matrix protein that is elevated in smooth muscleYrich regions of atherosclerotic plaques, was increased by nearly threefold in the estradiol-treated group. FBLN2 is a participant in smooth muscle cell migration via interactions with other extracellular matrix molecules such as hyaluronic acid and versican. 34 These data again suggest an enhancement of smooth muscle cell phenotypes in the lesion. The transcript for perlecan was also among the genes with significantly increased expression in the estrogen-treated group. Perlecan is also associated with the smooth muscle cell phenotype, and its increase in this model is consistent with observations in nonatherosclerotic castrated male rat carotid arteries. 35 Two signaling pathways were chosen for the confirmation of gene expression by real-time RT-PCR. These gene families were chosen because multiple members of the pathway were up-regulated in response to estrogen in both cases. Components of the IGF1 signaling pathway were chosen for follow-up studies because there exists a significant body of literature on this pathway and its estrogen responsiveness. The data reported here will add to that literature. The Wnt signaling pathway was chosen for follow-up confirmatory studies for the opposite reason. Although multiple components of the Wnt pathway were up-regulated in the iliac arteries in response to estrogen, only minimal information on the potential role of this pathway in the vasculature 36, 37 Vand no information on its estrogen response in the arteriesVwas found in the literature. IGF1 gene expression increased in the monkey iliac arteries in response to estradiol. Estradiol has been shown to increase IGF1 levels in other tissues such as uterine smooth muscle. 38 In contrast to the current data, we have shown that IGF1 decreased in the rat mesenteric arteries in response to ethinyl estradiol. 39 Similarly, Scheidegger et al 40 showed that estrogen caused a decrease in IGF1 expression in aortic smooth muscle cells. These data thus indicate a pleiotropic effect of estrogen on IGF1 in the vasculature. The differing responses of IGF1 to estrogen may be attributable to differences in vascular beds 41 or to the presence of atherosclerotic plaque in the monkey iliac arteries compared with rat mesenteric arteries or cultured aortic smooth muscle cells. IGF1 itself has pleiotropic effects on the vasculature. 42 IGF1 caused vasorelaxation in normotensive (but not hypertensive) rats, 43 and IGF1 has been reported to have atheroprotective 44 and atherogenic 45 effects, which may depend on the system and modulation by insulinlike growth factor binding proteins. It is intriguing to speculate whether some of the pleiotropic effects of estrogen on the vasculature are mediated by IGF1 because its effects are also pleiotropic. IGF binding proteins transport insulin-like growth factor and typically inhibit the access of the growth factor to its receptor. 46 Increased expression of IGF1, IGFBP4, and IGFBP5, as shown in this study, seems antithetical; further research will be required to determine which of these factors may mediate the positive versus negative effects of estrogen on the arteries.
Four genes related to the Wnt signal transduction pathway were up-regulated in the monkey iliac arteries in response to estradiol. Activation of the Wnt pathway has been reported to increase monocyte adhesion to endothelial cells, 47 a process critical to the development of atherosclerosis. SFRP2 and SFRP4 are inhibitors of the Wnt pathway; they are secreted soluble proteins that bind the ligand (Wnt) and prevent its binding to the receptor (called frizzled). 48 In this context, upregulation of SFRP2 and SFRP4 may mediate the protective effects of estradiol on the arteries. On the other hand, we have observed a down-regulation of SFRP4 in response to ethinyl estradiol and equilin in rat mesenteric arteries, 39 in a different species, in a different vascular bed, and in the absence of atherosclerosis. In contrast, LRP6 is a coreceptor for frizzled. 49 Up-regulation of LRP6 suggests an increased sensitivity of the Wnt pathway to ligand activation, which seems contradictory to the up-regulation of the inhibitors SFRP2 and SFRP4 described above. WISP2 (also called CCN5) expression is increased in response to the activation of the Wnt signaling pathway, 50 although its expression in other tissues has also been shown to increase in response to estrogen 51 and IGF1. 52 CCN proteins are cysteine-rich, modular proteins named for the first three proteins found to contain the modules. 53 CCN proteins, including WISP2/CCN5, are involved in adhesion, mitosis, extracellular matrix production, migration, and insulin-like growth factor binding. 53 Thus, WISP2/CCN5 may form a nexus of signaling for Wnt, estrogen, and IGF1 in the arteries. Additional research is necessary to identify the specific role of WISP2/CCN5, as well as of the other Wnt pathway components, in the vasculature.
CONCLUSIONS
The effects of estradiol on gene expression in the monkey iliac arteries may reflect alterations in both the proportions of individual cell populations and the modulation of individual phenotypes and gene expressions within those cell populations that occurred during the 8 months of estrogen treatment. In turn, individual cell population responses are likely to be different in a complex lesion of cellular heterogeneity than in purified cell populations in vitro or in a normal artery. Overall, the results suggest a shift toward extracellular matrix production phenotypes reflecting smooth muscle and fibroblastic contributions to arterial biology. Moreover, it is probable that the presence of atherosclerotic plaques and the heterogeneity of those plaques affect the gene expression responses of the arteries to estrogen. We observe little evidence to no evidence for increased arterial inflammation in these atherosclerotic arteries in response to estradiol.
